Equities Analysts Offer Predictions for Vaxcyte Q1 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Vaxcyte in a research note issued on Tuesday, February 25th. Leerink Partnrs analyst D. Risinger anticipates that the company will earn ($1.01) per share for the quarter. The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte's Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.39) EPS, FY2025 earnings at ($4.77) EPS, FY2026 earnings at ($5.46) EPS, FY2027 earnings at ($5.84) EPS, FY2028 earnings at ($5.17) EPS and FY2029 earnings at $1.63 EPS.

PCVX has been the topic of a number of other reports. Needham & Company LLC reiterated a "buy" rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group initiated coverage on Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 target price for the company. Guggenheim reissued a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Stock Down 2.6 %

NASDAQ:PCVX traded down $1.86 on Friday, reaching $70.24. 1,386,388 shares of the company's stock were exchanged, compared to its average volume of 1,150,914. The business has a fifty day moving average of $84.30 and a 200-day moving average of $94.91. Vaxcyte has a 52-week low of $58.10 and a 52-week high of $121.06. The firm has a market capitalization of $9.04 billion, a price-to-earnings ratio of -15.27 and a beta of 0.98.

Remove Ads

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14.

Insider Buying and Selling

In other news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company's stock, valued at $610,664.25. The trade was a 46.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the completion of the sale, the chief financial officer now owns 109,491 shares of the company's stock, valued at approximately $9,720,610.98. This trade represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 61,616 shares of company stock worth $5,225,971 in the last ninety days. 3.10% of the stock is owned by corporate insiders.

Institutional Trading of Vaxcyte

Several institutional investors and hedge funds have recently added to or reduced their stakes in PCVX. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte during the fourth quarter worth approximately $28,000. Blue Trust Inc. increased its stake in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after buying an additional 93 shares during the period. Smartleaf Asset Management LLC raised its position in Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI acquired a new stake in shares of Vaxcyte in the 4th quarter worth $41,000. Finally, Meeder Asset Management Inc. boosted its holdings in shares of Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after acquiring an additional 635 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.